M. Sanjeev

Structure-based elucidation of thiazine inhibitors targeting estrogen receptors alpha: pharmacophore modeling, virtual screening, molecular docking, MD, and DFT approach.

This research developed a promising lead molecule (HIT1) as a therapeutic approach for ER-positive breast cancer through pharmacophore model-based drug design of thiazine derivative targeting ERα via pharmacophore model-based drug design.